Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)

Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)

The purpose of this study is to determine the safety of an injection of coxsackievirus A21 into a melanoma tumour, and also to see if there is a tumour response.

Coxsackievirus A21, a naturally occurring enterovirus, has shown that in vivo it can infect and lyse melanoma. This study is to assess safety of a single intratumoural injection of the virus into an accessible subcutaneous melanoma metastasis.

Inclusion Criteria:

• stage IV melanoma (AJCC classification)
• minimum of 2 sc metastases
• failure or refusal of standard chemotherapy
• ECOG score of 0 or 1
• other

Exclusion Criteria:

• metastatic CNS disease
• ocular or mucosal melanoma
• immunodeficiency
• splenectomy
• other